Digest Network Come funziona
Network
/
Società
Co
Non verificato

Coya Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

51 comunicati stampa

Guarda tutti i comunicati
09/04/2026
Industria
Biotecnologia
Igiene alimentare
Salute
Sanità
Farmaceutica
Scienza
Psichiatria
Medicina - Varie
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
02/04/2026
Mercato del lavoro
Sanità
Scienza
Farmaceutica
Medicina - Varie
Biotecnologia
Igiene alimentare
Salute
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
18/03/2026
Analisi di mercato
Industria
Salute
Biotecnologia
Sanità
Scienza
Farmaceutica
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
16/03/2026
Psichiatria
Igiene alimentare
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Mercato azionario
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
10/02/2026
Web e Social Network
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
30/01/2026
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Finanza
Coya Therapeutics Announces $11.1 Million Private Placement
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
20/01/2026
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
08/01/2026
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Analisi di mercato
Industria
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
05/01/2026
Industria
Psichiatria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
23/12/2025
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Industria
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0